A Phase 3 trial compared tirzepatide to semaglutide in type 2 diabetes
Tirzepatide — Evidence
Clinical trials and publications sourced from ClinicalTrials.gov, PubMed, and FDA. Updated hourly by the automated crawler.
Claims and sources (2)
A Phase 3 trial studied tirzepatide in participants with obesity
Verified evidence (2)
Tirzepatide Versus Semaglutide Once Weekly in T2D
Phase 3 · COMPLETED · Started 2019
Tirzepatide in Participants With Obesity
Phase 3 · COMPLETED · Started 2019
Registered studies (50)
From the ClinicalTrials.gov record captured for this substance. Registration is not evidence of approval, efficacy, or safety.
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
Tirzepatide for the Treatment of Cannabis Use Disorder
GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity
Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay
Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health
INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants
Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes
Effectiveness of Combined GLP-1/GIP Dual Agonist Therapy and Structured Exercise on Skeletal Muscle Morphology, Quality, and Physical Function in Overweight and Obese Individuals
Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
GLP-1R Actions on Muscle and the Skeleton
24-h Energy Expenditure and Anti-obesity Medication
Real-World Tirzepatide Therapy in Post-Bariatric Weight Regain and Preoperative Obesity Patients
Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease
LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy
Tirzepatide-Based Prehabilitation Before Elective Ventral and Incisional Hernia Repair in Patients With Obesity
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
GLP-1s to Enhance Lasting Optimal Weight
Study of Patients Being Treated With Anti-obesity Medication
A Feasibility Study to Determine the Most Appropriate Digital Dietary Assessment Tool in Patients With Obesity Initiating GLP-1 Receptor Agonist Treatment
Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions
Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity
Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)
A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Tirzepatide for Alcohol Use Disorder
Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data
Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants
Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease
A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus
A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function
ClinicalTrials.gov (20)
A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer
Phase PHASE2 · NOT_YET_RECRUITING · Sponsor: National Cancer Institute (NCI)
Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients
Phase NA · NOT_YET_RECRUITING · Sponsor: Akhtar Saeed Medical and Dental College
Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy
Phase NA · NOT_YET_RECRUITING · Sponsor: Phenomix Sciences
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)
Phase PHASE1 · RECRUITING · Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Phase N/A · RECRUITING · Sponsor: Ohio State University
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Phase PHASE3 · RECRUITING · Sponsor: Eli Lilly and Company
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Phase PHASE3 · COMPLETED · Sponsor: Novo Nordisk A/S
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
Phase PHASE2 · RECRUITING · Sponsor: T. John Winhusen, PhD
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Phase PHASE3 · ACTIVE_NOT_RECRUITING · Sponsor: Eli Lilly and Company
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Phase PHASE3 · RECRUITING · Sponsor: Eli Lilly and Company
Tirzepatide in MetALD
Phase PHASE2 · RECRUITING · Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
Phase PHASE4 · ENROLLING_BY_INVITATION · Sponsor: Mayo Clinic
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Phase PHASE3 · RECRUITING · Sponsor: Eli Lilly and Company
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
Phase PHASE4 · RECRUITING · Sponsor: Weill Medical College of Cornell University
A Study to Evaluate ALN-2232 in Participants With Obesity
Phase PHASE1/PHASE2 · RECRUITING · Sponsor: Alnylam Pharmaceuticals
Multi-Site Trial of Tirzepatide for Smoking Cessation
Phase PHASE2 · RECRUITING · Sponsor: University of Southern California
Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV
Phase PHASE4 · ENROLLING_BY_INVITATION · Sponsor: National Taiwan University Clinical Trial Center
Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients
Phase PHASE4 · NOT_YET_RECRUITING · Sponsor: Yunlong Wang
Effects of GLP-1 RAs on Human Lactation Outcomes
Phase N/A · RECRUITING · Sponsor: University of Colorado, Denver
Salivary Function and Dental Changes During GLP-1 Therapy
Phase N/A · NOT_YET_RECRUITING · Sponsor: Bilecik Seyh Edebali Universitesi
PubMed (27)
Effect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study.
BMC endocrine disorders · 2026 Jul 16 · DOI: 10.1186/s12902-026-02422-8
Tirzepatide as a therapeutic tool for kidney impairment in obesity: insights from a real-world study.
Journal of translational medicine · 2026 Jul 16 · DOI: 10.1186/s12967-026-08558-4
Urological Complications of Morbid Obesity and the Role of Bariatric Surgery and Glucagon-Like Peptide-1 Receptor Agonists in Their Management: A Systematic Review.
Cureus · 2026 Jun · DOI: 10.7759/cureus.110952
Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.
Journal of the American Heart Association · 2026 Jul 17 · DOI: 10.1161/JAHA.125.047018
Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide.
Surgical endoscopy · 2026 Jul 17 · DOI: 10.1007/s00464-026-13147-z
Obese and overweight patients with type 2 diabetes mellitus are not treated optimally - an overview of current clinical practice and future perspectives.
Expert review of clinical pharmacology · 2026 Jul 21 · DOI: 10.1080/17512433.2026.2706660
Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand.
JAMA health forum · 2026 Jul 2 · DOI: 10.1001/jamahealthforum.2026.2207
Hyperuricemia, gout and obesity: should weight management be more of a focus in gout management?
Nutrition, metabolism, and cardiovascular diseases : NMCD · 2026 Jul 9 · DOI: 10.1016/j.numecd.2026.104860
Coronary artery disease -related outcomes associated with semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.
Nutrition, metabolism, and cardiovascular diseases : NMCD · 2026 Jul 7 · DOI: 10.1016/j.numecd.2026.104859
GLP-1 Receptor Agonists and All-Cause Overdose Risk in Veterans With Type 2 Diabetes and Opioid Use Disorder.
The Journal of clinical psychiatry · 2026 Jul 15 · DOI: 10.4088/JCP.25m16212
Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Endocrinology, diabetes & metabolism · 2026 Jul · DOI: 10.1002/edm2.70291
Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
Obesity pillars · 2026 Sep · DOI: 10.1016/j.obpill.2026.100300
Tirzepatide-Induced Weight Loss and Exacerbation of Bipolar Disorder With Clozapine Treatment: A Case Report.
Journal of clinical psychopharmacology · 2026 Jul 24 · DOI: 10.1097/JCP.0000000000002241
Papular granuloma annulare associated with tirzepatide: A case report.
JAAD case reports · 2026 Aug · DOI: 10.1016/j.jdcr.2026.06.046
Tirzepatide and the gut microbiota-obesity axis: metabolic mechanisms and therapeutic perspectives.
Frontiers in microbiology · 2026 · DOI: 10.3389/fmicb.2026.1901528
Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.
Annals of the American Thoracic Society · 2026 Jul 21 · DOI: 10.1093/annalsats/aaoag177
GLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans.
Biological psychiatry · 2026 Jul 21 · DOI: 10.1016/j.biopsych.2026.06.033
Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study.
BMJ open · 2026 Jul 21 · DOI: 10.1136/bmjopen-2025-109259
Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials.
Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026 Jul 22 · DOI: 10.1111/obr.70198
Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.
Pharmacological reports : PR · 2026 Jul 22 · DOI: 10.1007/s43440-026-00879-x
Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
Endocrinology, diabetes & metabolism · 2026 Jul · DOI: 10.1002/edm2.70291
Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report.
Clinical case reports · 2026 Jul · DOI: 10.1002/ccr3.73183
Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
Journal of the Endocrine Society · 2026 Aug · DOI: 10.1210/jendso/bvag149
Effects of tirzepatide therapy on body weight and body composition in adults with overweight and obesity.
Frontiers in endocrinology · 2026 · DOI: 10.3389/fendo.2026.1834580
Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.
JACC. Advances · 2026 Jul · DOI: 10.1016/j.jacadv.2026.102917
Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
Obesity pillars · 2026 Sep · DOI: 10.1016/j.obpill.2026.100300
One receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy.
Appetite · 2026 Jul 23 · DOI: 10.1016/j.appet.2026.108723